看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
2 t0 N# x- y2 d0 P$ j( t
) B: r( b' d7 v: }: @! Q) y
6 o0 {8 p0 @2 Y' y: z3 dCurrently available feasibility data for possible combination strategies.
/ w) g, h k8 M4 i————————————————————————————————
6 J- R* w1 _3 y$ M8 T2 kCombination Feasibility according to preliminary data , N& D) _% K! @6 S& |8 e) q3 h
——————————————————————————————————& v& E0 E) p& b
Bevacizumab + sorafenib Yes, reduced dose ( c- e$ P: _0 q
Bevacizumab + sunitinib† No
: H+ K# z. ^7 I% w8 tBevacizumab + temsirolimus Yes
7 e, P0 _$ D/ CBevacizumab + everolimus Yes
$ S e+ ?4 k* {/ W# }Sorafenib + sunitinib ?
; g( \0 L, I( ?2 I8 b& X8 i& l6 zSorafenib + temsirolimus Yes, reduced dose
x- E& D7 @' R) V% JSorafenib + everolimus Yes, reduced dose . l# N+ r2 P, v! S3 c) h
Sunitinib + temsirolimus† No ) @1 J+ N) j3 Z) M4 U- z1 o) l
Sunitinib + everolimus ? 0 c0 `5 k% ?$ t+ Z$ P
Temsirolimus + everolimus ?
; m' W' Q9 g0 b3 I! n% ^% N————————————————————: U, \6 ` |7 A; x3 w
†Led to US FDA warning.* |; f9 {& S0 Z* Q1 m6 Q
?: As yet unattempted combination.
' v5 @# U) ]$ X0 W6 F* Z |